EUCTR2005-001388-71-IT进行中（未招募）不适用
A phase 2 randomized, parallel-arm study of oral direct factor Xa-inhibitor apixaban and low molecular weight heparin or fondaparinux with a vitamin K antagonist in subjects with acute symptomatic deep vein thrombosis.
BRISTOL-M.SQUIBB0 个研究点目标入组 660 人开始时间: 2007年1月18日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 660
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A Phase 2 Randomized, Parallel-Arm Study of Oral Direct Factor Xa-Inhibitor Apixaban and Low Molecular Weight Heparin or Fondaparinux With A Vitamin K Antagonist In Subjects With Acute Symptomatic Deep-Vein Thrombosis.Revised Protocol 02, Incorporates Amendments 02, 04 and Administrative Letter dated 14-Apr-2006;+ Pharmacogenetics Blood Sample Amendment version 01 dated 29-June-2005. - BotticelliAcute Symptomatic Deep Vein ThrombosisEUCTR2005-001388-71-CZBristol-Myers Squibb International Corporation660
进行中（未招募）
不适用
A Phase 2 Randomized, Parallel-Arm Study of Oral Direct Factor Xa-Inhibitor Apixaban and Low Molecular Weight Heparin or Fondaparinux With A Vitamin K Antagonist In Subjects With Acute Symptomatic Deep-Vein Thrombosis.Revised Protocol 02, Incorporates Amendments 02, 04 and Administrative Letter dated 14-Apr-2006;+ Pharmacogenetics Blood Sample Amendment version 01 dated 29-June-2005. - BotticelliEUCTR2005-001388-71-SEBristol-Myers Squibb International Corporation660
进行中（未招募）
不适用
A Phase 2 Randomized, Parallel-Arm Study of Oral Direct Factor Xa-Inhibitor Apixaban and Low Molecular Weight Heparin or Fondaparinux With A Vitamin K Antagonist In Subjects With Acute Symptomatic Deep-Vein Thrombosis.Protocol version 3.0 dated 29-June-2005 - BotticelliEUCTR2005-001388-71-ATBristol-Myers Squibb International Corporation660
进行中（未招募）
不适用
A Phase 2 Double-Blind Randomized Study of Oral Enzastaurin HCl versus Placebo Concurrently with Pemetrexed (Alimta) as Second-Line Therapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer - NDEUCTR2006-006698-25-ITELI LILLY160
进行中（未招募）
不适用
A Phase 2 Double-Blind Randomized Study of Oral Enzastaurin HCl versus Placebo Concurrently with Pemetrexed (Alimta®) as Second Line Therapy in Patients with Advanced or Metastatic Non Small Cell Lung Cancer - N/AAdvanced or Metastatic Non Small Cell Lung CancerMedDRA version: 9.1Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSEUCTR2006-006698-25-DEEli Lilly and Company Limited160